Suppr超能文献

RAS 效应蛋白的功能和结构见解。

Functional and structural insights into RAS effector proteins.

机构信息

Department of Biochemistry and Molecular Pharmacology, NYU Grossman School of Medicine, New York, NY, USA; Laura and Isaac Perlmutter NYU Cancer Center, NYU Langone Health, New York, NY, USA.

NCI RAS Initiative, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

出版信息

Mol Cell. 2024 Aug 8;84(15):2807-2821. doi: 10.1016/j.molcel.2024.06.027. Epub 2024 Jul 17.

Abstract

RAS proteins are conserved guanosine triphosphate (GTP) hydrolases (GTPases) that act as molecular binary switches and play vital roles in numerous cellular processes. Upon GTP binding, RAS GTPases adopt an active conformation and interact with specific proteins termed RAS effectors that contain a conserved ubiquitin-like domain, thereby facilitating downstream signaling. Over 50 effector proteins have been identified in the human proteome, and many have been studied as potential mediators of RAS-dependent signaling pathways. Biochemical and structural analyses have provided mechanistic insights into these effectors, and studies using model organisms have complemented our understanding of their role in physiology and disease. Yet, many critical aspects regarding the dynamics and biological function of RAS-effector complexes remain to be elucidated. In this review, we discuss the mechanisms and functions of known RAS effector proteins, provide structural perspectives on RAS-effector interactions, evaluate their significance in RAS-mediated signaling, and explore their potential as therapeutic targets.

摘要

RAS 蛋白是保守的鸟苷三磷酸(GTP)水解酶(GTPases),作为分子双稳态开关,在许多细胞过程中发挥着重要作用。当与 GTP 结合时,RAS GTPases 采用一种活性构象,并与特定的蛋白质相互作用,这些蛋白质被称为 RAS 效应物,它们含有保守的泛素样结构域,从而促进下游信号转导。在人类蛋白质组中已经鉴定出超过 50 种效应蛋白,其中许多已被研究为 RAS 依赖性信号通路的潜在介质。生化和结构分析为这些效应物提供了机制上的见解,使用模式生物的研究补充了我们对它们在生理和疾病中的作用的理解。然而,关于 RAS-效应物复合物的动力学和生物学功能的许多关键方面仍有待阐明。在这篇综述中,我们讨论了已知的 RAS 效应蛋白的机制和功能,提供了 RAS-效应物相互作用的结构视角,评估了它们在 RAS 介导的信号转导中的意义,并探讨了它们作为治疗靶点的潜力。

相似文献

1
Functional and structural insights into RAS effector proteins.RAS 效应蛋白的功能和结构见解。
Mol Cell. 2024 Aug 8;84(15):2807-2821. doi: 10.1016/j.molcel.2024.06.027. Epub 2024 Jul 17.
8

本文引用的文献

1
RAS and SHOC2 Roles in RAF Activation and Therapeutic Considerations.RAS和SHOC2在RAF激活中的作用及治疗考量
Annu Rev Cancer Biol. 2024 Jun;8:97-113. doi: 10.1146/annurev-cancerbio-062822-030450. Epub 2023 Dec 5.
4
The energetic and allosteric landscape for KRAS inhibition.KRAS抑制的能量和变构格局。
Nature. 2024 Feb;626(7999):643-652. doi: 10.1038/s41586-023-06954-0. Epub 2023 Dec 18.
5
Novel therapeutic perspectives in Noonan syndrome and RASopathies.努南综合征和 RAS 病相关疾病的新治疗视角。
Eur J Pediatr. 2024 Mar;183(3):1011-1019. doi: 10.1007/s00431-023-05263-y. Epub 2023 Oct 21.
8
Defining bone fide effectors of RAS GTPases.定义 RAS GTPases 的真正效应器。
Bioessays. 2023 Sep;45(9):e2300088. doi: 10.1002/bies.202300088. Epub 2023 Jul 4.
9
Pan-KRAS inhibitor disables oncogenic signalling and tumour growth.泛 KRAS 抑制剂使致癌信号和肿瘤生长失活。
Nature. 2023 Jul;619(7968):160-166. doi: 10.1038/s41586-023-06123-3. Epub 2023 May 31.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验